Data from clinical studies performed with a recombinant grass pollen allergy vaccine published

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P, Focke-Tejkl M, Schmutz R, Lemell P, Zieglmayer R, Weber M, Kiss R, Blatt K, Valent P, Stolz F, Huber H, Neubauer A, Knoll A, Horak F, Henning R, Valenta R.
EBioMedicine. 2016 Aug 20. pii: S2352-3964(16)30371-1. doi: 10.1016/j.ebiom.2016.08.022
www.ncbi.nlm.nih.gov/pubmed/27650868

Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection.
Cornelius C, Schöneweis K, Georgi F, Weber M, Niederberger V, Zieglmayer P, Niespodziana K, Trauner M, Hofer H, Urban S, Valenta R.
EBioMedicine. 2016 Aug 8. pii: S2352-3964(16)30329-2. doi: 10.1016/j.ebiom.2016.07.023
www.ncbi.nlm.nih.gov/pubmed/27568223

Development of an Allergy Immunotherapy Leads to a New Type of Hepatitis B Vaccine.
Gerlich WH, Glebe D.
EBioMedicine. 2016 Jul 27. pii: S2352-3964(16)30342-5. doi: 10.1016/j.ebiom.2016.07.032
www.ncbi.nlm.nih.gov/pubmed/27485030